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Interleukin-1 (IL-l) has protean effects in the pathogene- 
sis of rheumatoid arthritis (RA). These effects include pro- 
duction of prostaglandins and collagenase from rheumatoid 
fibroblasts as well as upregulation of adhesion molecule ex- 
pression on these cells. IL-1 can activate monocytes and 
neutrophils, as well as promote the growth of fibroblasts and 
endothelial cells. Recently, a novel interleukin-1 receptor 
antagonist protein (IRAP) has been isolated, purified, 
cloned, and expressed, which may modulate the effects of 
IL-l. In this study, we present data demonstrating that mac- 
rophages isolated from human RA synovial tissues express 
both IL-1 and IRAP genes. In addition, RA synovial tissue 
macrophages and lining cells display IL-l and IRAP anti- 
genie expression by immunohistochemistry. In contrast, os- 
teoarthritis synovial tissues, as compared to RA, have fewer 
IL-1 and IRAP-positive macrophages. Thus, the production 
of IL-1 balanced by IRAP may affect the joint destruction 
found in these diseases. o lwz Academic PRSS, IW. 
INTRODUCTION 
The rheumatoid (RA) synovial tissue is character- 
ized by infiltrating mononuclear cells, proliferating fi- 
broblasts, and endothelial cells (1). The pathogenesis of 
synovial inflammation is mediated by both cellular 
and humoral interactions (2). A number of humoral 
mediators including cytokines such as interleukin-1 
(IL-l) have been implicated in the evolution of the ero- 
sive arthritis associated with RA (3). 
IL-1 is a 17-kDa cytokine that is produced by im- 
mune and nonimmune cells that has pleiotropic effects 
predominant form synthesized and released in the su- 
pernatants of stimulated cells (3,4). IL-1 can mediate 
a variety of effects that may contribute to the patho- 
genesis of RA. These effects include stimulation of en- 
dothelial cell-derived adherence proteins and produc- 
tion of fibroblast-derived prostaglandin E, and collage- 
nase (4-S). 
Joint inflammation and subsequent evolution to 
joint destruction may result from a delicate balance 
between the production of proinflammatory cytokines 
and cytokine inhibitors. Recently an IL-1 receptor an- 
tagonist protein, termed IRAP, has been isolated, pu- 
rified, cloned, and expressed (9, 10). Exposure of pe- 
ripheral blood monocytes to adherent IgG or granulo- 
cyte-macrophage colony stimulating factor promote 
the expression of IRAP from these cells (3,11-13). This 
protein functions as a competitive inhibitor of IL-1 at 
the level of the receptor. Although the production of 
IL-1 and IRAP by blood monocytes has been assessed, 
little is known regarding the production of this protein 
by cells obtained from inflammatory lesions. In this 
study we report that RA synovial tissue macrophages 
express mRNA for IL-1 and IRAP. Furthermore, RA 
synovial tissue macrophages and macrophage-derived 
synovial lining cells were demonstrated to have IL-l-p 
and IRAP antigen expression by immunohistochemical 
localization. 
MATERIALS AND METHODS 
Patients Studied and Cell Isolation 
on a variety of cells (3,4). Both IL-l-& and IL-l-p bind 
the same receptor; however, IL-l-p seems to be the Synovial tissues were obtained from eight patients 
with RA at the time of total joint replacement. For 
”  ”  
comparison with the RA samples, synovial tissues 
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dispase, DNAase, and collagenase as described previ- 
ously (16, 17). The resultant single-cell suspensions 
were fractionated into density-defined subpopulations 
by isopyknic centrifugation through continuous pre- 
formed Percoll gradients (Pharmacia, Piscataway, NJ). 
Macrophages were enriched by adherence to fibronec- 
tin-coated collagen gels and selective trypsinization 
(incubation with trypsin:EDTA for 5-10 min) (15, 16). 
Macrophages were harvested from the collagen gels by 
treatment with clostridial collagenase and found to be 
290% pure, as assessed by F, receptor-mediated 
phagocytosis of IgG opsonized sheep red blood cells, 
esterase staining, and staining with commercial anti- 
macrophage monoclonal antibodies OKMl (Ortho Di- 
agnostics, Raritan, NJ) and anti-LeuM3 (Becton- 
Dickinson, Mountain View, CA). The endotoxin con- 
centration of the tissue culture medium was CO.05 ng/ 
ml as determined by the Limulus assay (Associates of 
Cape Code, Woods Hole, MA). 
Mononuclear cells were isolated from normal volun- 
teers by Ficoll-Hypaque density centrifugation as de- 
scribed (18). 
Northern Blot Analysis 
Total cellular RNA was obtained from 2.5 x lo6 RA 
macrophages using a modification of Chirgwin and as- 
sociates and Jonas and associates (19-21). Briefly, cells 
were placed in a solution containing 25 mM Tris, pH 
8.0, 4.2 M guanidine isothiocyanate, 0.5% Sarkosyl, 
and 0.1 M 2-mercaptoethanol. After homogenization, 
the suspension was added to a solution containing an 
equal volume of 100 mM Tris, pH 8.0, 10 mM EDTA, 
and 1% SDS. The mixture was then extracted with 
chloroform-phenol and chloroform-isoamyl alcohol. 
The RNA was alcohol precipitated and the pellet dis- 
solved in diethylpyrocarbonate-treated HzO. Total 
RNA was separated by Northern analysis using form- 
aldehyde, 1% agarose gels, transblotted onto nitrocel- 
lulose, baked, prehybridized, and hybridized with a 
32P-5’ end-labeled oligonucleotide probe. A 30-mer oli- 
gonucleotide probe was synthesized using the pub- 
lished cDNA sequence for human-derived IRAP (10). 
The probe was complementary to nucleotides 438-468 
and had the sequence 5’-TGT-GCA-GAG-GAA-CCA- 
ACC-GGG-GCA-GGC-GGC-3’. A 30-mer oligonucle- 
otide probe was synthesized using the published cDNA 
sequence for IL-l-8 (22). The probe was complemen- 
tary to nucleotides 166 ,through 195 and had the se- 
quence 5’-CGC-GGC-CTG-CCT-GAA-GCC-CTT-GCT- 
GTA-GTG-3’. Equivalent amounts of total RNA/gel 
were assessed by monitoring 28s and 18s rRNA. 
Immunohistochemistry of Synovial Tissues 
Antibodies used. Murine monoclonal anti-IL-l-8 and 
anti-IRAP (monoclonal antibody 14) were obtained 
from the Upjohn Co. (Kalamazoo, MI). Irrelevant 
mouse monoclonal antibodies were used as negative 
controls. 
Immunoalkaline Phosphatase Staining 
Immunoalkaline phosphatase staining was per- 
formed on formalin-fixed, paraffin-embedded RA syno- 
vial tissues (23). Tissue sections (5-7 km) mounted on 
poly+lysine-coated glass slides were deparaffinized 
and rehydrated in a graded series of xylene and etha- 
nol solutions. The slides were treated with avidin for 
15 min at room temperature followed by biotin (1:50 in 
goat blocking serum, room temperature) to block bind- 
ing sites for these molecules (Vector Laboratories, 
Mountain View, CA). The slides were exposed to opti- 
mal dilutions of specific antibody or control antibody. 
After incubating for 20 min at 37°C the slides were 
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FIG. 1. (A) A representative experiment showing IRAP gene ex- 
pression by isolated RA synovial tissue macrophages from two pa- 
tients. One of these samples was obtained from RA patient number 
4 (Table 1). (B) 18s and 28s r-RNA corresponding to (A). (C) A rep- 
resentative experiment showing IL-l-8 gene expression by isolated 
macrophages from the same two patients. (D) 18s and 285 rRNA 
corresponding to (C). (E) A representative experiment showing lack 
of IRAP gene expression in normal peripheral blood mononuclear 
cells. (Fl 18s and 28s rRNA corresponding to (E). 
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rinsed with phosphate-buffered saline (X 31, overlaid 
with biotinylated secondary antibodies (Biogenex, San 
Ramon, CA), and .incubated another 20 min at 37°C 
followed by a phosphate-buffered saline (PBS) wash. 
Sections were treated with alkaline phosphatase- 
labeled streptavidin (Biogenex) for 20 min at 37”C, 
rinsed in PBS, and overlaid with Vector red substrate 
chromogen containing 150 r&f NaCl and 10 mM le- 
vamisole (Vector) for 20 min at room temperature. 
Mayer’s hematoxylin was used as a counterstain. 
Microscopic Analysis of Immunohistochemistry 
Each tissue was assigned an inflammatory score 
from 1 to 4, with 4 representing the greatest amount of 
mononuclear cell infiltrate. In addition, a macrophage 
score was determined based on cell morphology to in- 
dicate the relative amount of macrophages present in a 
tissue. Macrophage scores ranged from 1 to 4, with 4 
representing the greatest number of macrophages as 
previously described (24). Each tissue was reviewed by 
two pathologists and scored in a blinded fashion to de- 
termine the approximate percentage of macrophages, 
synovial lining cells, and endothelial cells reactive 
with the monoclonal antibodies. 
Statistical Analysis 
Correlation coefficients were determined by regres- 
sion analysis. Differences between the mean values of 
groups was determined using a paired Student t test. P 
values co.05 were considered significant. 
RESULTS 
Gene Expression of IL-l -f3 and IRAP by RA Synovial 
Tissue Macrophuges 
Northern Blot analysis of mRNA isolated from puri- 
fied macrophages from patients with RA is shown in 
Fig. 1. Figure 1A shows steady state IRAP mRNA from 
two patients with RA. Figure 1B shows 18s and 28s 
rRNA corresponding to (A). Figure 1C shows steady 
state IL-l-p mRNA from the same patients along with 
18s and 28s rRNA (D). Normal peripheral blood mono- 
cytes do not express IRAP (E and F) and require exog- 
enous stimulation prior to expression of IRAP mRNA. 
In contrast, RA macrophages express both IRAP and 
IL-1 mRNA without exogenous stimuli. 
Antigenic Expression of IL-l -f3 and IRAP by RA 
Synovial Tissue Macrophages 
Since RA synovial macrophages were found to ex- 
press both IL-l-l3 and IRAP mRNA, we determined 
whether this mRNA was translated to protein. Forma- 
lin-fixed, paraffin-embedded sections of synovial tis- 
sues were obtained from seven patients and six OA 
patients. Sections were immunostained with anti- 
IRAP (Table 1) and in selected cases with anti-IL-l-@. 
In general, the RA tissues had higher inflammatory 
scores than the OA tissues (2.3 + 0.3 versus 1.2 + 0.2) 
(means + SE). In addition, the numbers of macro- 
phages present within the RA synovial tissues were 
TABLE 1 




score0 M+ score+ 
(1-Q (l-4 % of m+s+ 
% of lining 
cells + % of m+s+ 
% of lining 

















Mean * SE 
32/M 2 3 95 95 55 60 
65/F 4 4 80 100 a5 85 
33/F 1 2 0 1 ND ND 
73/F 2 4 20 10 90 95 
401F 2 2 40 15 5 30 
67/F 2 3 0 0 ND ND 
-IF 3 4 60 90 ND ND 
52 2.3 f 0.3 3.1 k 0.3 42 5 13 44 + 16 58 f 17 68 2 13 
60/F 1 1 7 50 30 90 
65/F 1 1 8 5 25 35 
73/F 1 1 30 25 ND ND 
70/F 1 1 2 60 10 * 
89lF 1 1 0 70 60 70 
88/F 2 1 10 95 5 30 
67 1.2 f 0.2 1.0 9.6 f 4 50.8 2 11 26 2 8 56 2 12 
Note. F, female; M, male; ND, not done. M+ = macrophage. 
“Tissues were assigned an inflammatory score with 1 being the least amount of inflammation and 4 being the greatest amount of 
infkmmation. 
b Tissues were assigned a macrophage score with 1 being the least amount of macrophages and 4 being the greatest. 
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greater than found within the OA tissues (3.1 + 0.3 
versus 1.0). 
In RA, IRAP expression was noted in the synovial 
lining layer with 44 ? 16% of cells reacting with anti- 
IRAP (Table 1, Fig. 2). OA tissues also exhibited syno- 
vial lining layer IRAP reactivity (Table 1, Fig. 3). 
In RA synovial tissues, macrophages located in the 
subsynovial areas expressed IRAP, with 42 + 13% of 
macrophages staining positively as compared to only 
9.6 + 4% of the macrophages obtained from OA immu- 
nostaining positive for IRAP. Although RA macro- 
phages that were immunopositive for IRAP were prin- 
cipally distributed in the subsynovial region, perivas- 
cular macrophages were also immunopositive for 
IRAP. There was a positive relationship between the 
percentage of macrophages staining with anti-IRAP in 
RA and the macrophage score (r = 0.38) or the inflam- 
matory score (r = 0.631, although neither correlation 
reached statistical significance. The minority of RA tis- 
sues displayed IRAP positive vascular endothelial 
cells. In addition, fibroblasts and lymphocytes located 
in the synovial tissues of RA patients did not express 
IRAP. 
Representative RA synovial tissues were stained 
with anti-IL-l-l3 (Table 1, Fig. 2). IL-l-l3 reactivity was 
present on the majority of macrophages (58 4 17%) and 
lining cells (68 + 13%). In contrast, a smaller percent- 
age of macrophages in OA (26 + 8) were IL-l-l3 positive 
(Table 1, Fig. 3). 
DISCUSSION 
IL-1 has been implicated as an important factor me- 
diating inflammation and joint destruction in RA (3). 
Attempts to measure bioactivity in human synovial 
fluids have often resulted in conflicting results, per- 
haps due to the presence of IL-l inhibitors in these 
fluids (3, 25, 26). More recently, IL-l measured by 
ELISA demonstrated significantly increased levels of 
IL-l in RA synovial fluids (3, 25, 27). Synovial fluid 
cells in vitro do not appear to produce increased levels 
of IL-l (3); however, rheumatoid synovial tissue in 
vitro synthesizes both IL-l-a and IL-l-l3 (28). Firestein 
and associates using in situ hybridization techniques 
have shown that approximately 10% of the cells dis- 
persed from RA synovial tissues expressed IL-l-p 
mRNA. Furthermore, cells that were expressing con- 
stitutive IL-l-l3 were the macrophage-enriched OKMl- 
positive cell population (29). Interestingly, these stud- 
ies failed to demonstrate IL-l-p mRNA expression 
from synovial fluid monocytes, suggesting potential 
disparate IL-l-l3 production between monocytes from 
synovial fluid and synovial tissue macrophages. 
IRAP, a naturally occurring competitive inhibitor of 
IL-l at the level of the IL-l receptor, may serve to 
modulate IL-l effects. The relative amounts of IL-l-9 or 
IRAP synthesized by blood monocytes in culture de- 
pend upon the immunologic stimulus, and it appears 
that the same population of monocytes secrete both 
proteins (30). IRAP production is stimulated by adher- 
ence of monocytes to IgG, but this production can be 
counteracted by lipopolysaccharide stimulation of the 
cells (30). When peripheral blood monocytes are differ- 
entiated in culture to monocyte-derived macrophages, 
their production of IRAP increases, particularly in the 
presence of granulocyte-macrophage colony stimulat- 
ing factor. In contrast, IL-l-p production is low in these 
cells (3, 11, 12, 13). Malyak et al. have recently ana- 
lyzed synovial fluids for the presence of IRAP by 
ELISA and found that IRAP levels are increased in RA 
as well as other arthritic disorders such as gouty ar- 
thritis (31). The origin of the cells liberating IRAP into 
synovial fluids was not examined. 
In this study we have confirmed the production of 
IL-l-p by purified RA macrophages freshly isolated 
from the inflamed synovial tissue. In addition, we have 
shown that this same population of cells constitutively 
produce IRAP, unlike normal blood monocytes which 
exhibit little, if any, transcription of either IL-l-l3 or 
IRAP mRNA without in vitro stimulation. Moreover, 
immunohistochemical localization of both IL-1 and 
IRAP antigens are found on RA synovial tissue mac- 
rophages as well as synovial lining cells. These find- 
ings indicate that tissues containing significant num- 
bers of inflammatory cells, presumably secrete high 
levels of cytokines and contain an increased percent- 
age of IRAP-positive macrophages. Furthermore, in- 
flammatory cells within OA tissues such as macro- 
phages are likely to secrete lower levels of some cyto- 
kines including IRAP. Thus, a greater percentage of 
RA, as compared to OA, subsynovial macrophages ex- 
press IRAP. Furthermore, these data indicate that in 
the context of RA, the same population of synovial tis- 
sue macrophages can both mediate erosive joint de- 
struction, via the production of IL-l, and also modulate 
this destruction by the production of IRAP in an auto- 
crine and paracrine fashion. The net biological effect of 
IL-1 may be substantially regulated by the production 
of IRAP by synovial macrophages within the RA joint. 
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